Overview

This briefing summarises the latest business, regulatory and legal developments in China for drug, device, life science and health care companies. Included in this edition are details on the following:

- Swiss drugmaker Novartis expands in China.

- China plans to divide emergency patients into four classes for medical treatment.

- China's biopharmaceutical industry to accelerate internationalisation.

- Cardinal Health Inc to continue acquisitions in China.

- Notice on circulation of the guidelines for monitoring adverse events involving medical devices.

- Letter on soliciting public comments on communication methods for responsible food and drug safety.

For the full details on all these stories and more, click 'View Briefing'.